Related Experiment Videos
Tonographic Outflow Facility and Intraocular Pressure After Standalone OMNI Surgery
Andrew J Swampillai1,2, Thomas Sherman1,2, Ananth Ranjit1,2
1KCL Frost Eye Research Department, St. Thomas' Hospital, Westminster Bridge Road.
Journal of Glaucoma
|July 3, 2026
Summary
The OMNI surgical device initially reduced intraocular pressure (IOP) and improved outflow facility in glaucoma patients. However, these positive effects were not statistically significant at the 12-month follow-up.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Medical Devices
Background:
- Glaucoma involves elevated intraocular pressure (IOP) due to outflow resistance.
- The OMNI device targets conventional outflow pathways.
- Minimally invasive glaucoma surgery (MIGS) aims to reduce IOP and preserve vision.
Purpose of the Study:
- To evaluate the standalone efficacy of the OMNI device in managing glaucoma.
- To assess changes in intraocular pressure (IOP) and tonographic outflow facility (TOF) post-treatment.
- To determine the durability of OMNI device effects at 12 months.
Main Methods:
- Prospective study of 30 patients with uncontrolled open-angle glaucoma or ocular hypertension.
- Baseline IOP and TOF measurements after a 4-week medication washout.
- Standalone OMNI device implantation (360° canaloplasty and 160-180° trabeculotomy).
- Repeat IOP and TOF measurements at 3 and 12 months post-surgery.
Main Results:
- At 3 months, a statistically significant reduction in IOP (3.26 mmHg) and increase in TOF (P=0.0002) were observed.
- At 12 months, mean IOP reduction was 1.57 mmHg (P=0.6), and TOF changes were not significant (P=0.07).
- Long-term efficacy beyond 3 months was limited, with only 32% achieving >20% IOP reduction at 12 months.
Conclusions:
- The OMNI device demonstrated initial IOP reduction and improved TOF at 3 months.
- Sustained IOP and TOF improvements were not statistically significant at 12 months.
- This study provides insights into the standalone OMNI device's short-term and long-term effects in glaucoma management.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...